<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603600</url>
  </required_header>
  <id_info>
    <org_study_id>945</org_study_id>
    <nct_id>NCT03603600</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and effectiveness of the enVista
      trifocal intraocular lens when implanted in the capsular bag.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataracts are a common condition in adults over 40 years of age, and surgical replacement of
      the cataractous lens with an intraocular lens (IOL) remains an effective way to restore
      vision to cataract patients.The objective of the study is to evaluate the safety and
      effectiveness of the enVista trifocal intraocular lens when implanted in the capsular bag.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 334 subjects will be implanted bilaterally with the enVista MX60EF trifocal MIOL, and approximately 167 control subjects will be implanted bilaterally with the enVista MX60E monofocal IOL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The Investigator implanting the IOL and designated site personnel will be unmasked to the assignment of IOLs. Subjects and designated postoperative evaluator(s) will be masked to the IOLs assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Photopic monocular best-corrected distance visual acuity (BCDVA)</measure>
    <time_frame>Day 120 to Day 180</time_frame>
    <description>Photopic monocular best-corrected distance visual acuity (BCDVA) in first implanted eyes at Post-Operative Visit 4 (Day 120 to 180 after second eye implantation)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">501</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>enVista MX60EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enVista MX60EF (trifocal) multifocal IOL (MIOL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enVista MX60E</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>enVista MX60E monofocal IOL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enVista MX60E</intervention_name>
    <description>enVista MX60E monofocal IOL</description>
    <arm_group_label>enVista MX60E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enVista MX60EF</intervention_name>
    <description>enVista MX60EF (trifocal) multifocal IOL (MIOL)</description>
    <arm_group_label>enVista MX60EF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be 22 years of age or older on the date the Informed Consent Form (ICF)
             is signed.

          2. Subjects must have the capability to understand and provide written informed consent
             on the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved
             Informed Consent Form (ICF) and authorization as appropriate for local privacy
             regulations.

          3. Subjects must have a BCDVA equal to or worse than 20/40 in each eye, with or without a
             glare source, due to a clinically significant cataract (cortical, nuclear,
             subcapsular, or combination) that is considered amenable to treatment with standard
             phacoemulsification cataract extraction and capsular IOL implantation.

          4. Subjects must have a BCDVA projected to be better than 20/32 after IOL implantation in
             each eye, as determined by the medical judgment of the Investigator or measured by
             potential acuity meter (PAM) testing, if necessary.

          5. Subjects must have clear intraocular media other than the cataract in both eyes.

        Exclusion Criteria:

          1. Subjects who have participated in any drug or device clinical investigation within 30
             days prior to entry into this study and/or will participate in another investigation
             during the period of study participation.

          2. Subjects who have any corneal pathology (e.g., significant scarring, guttata,
             inflammation, edema, dystrophy, etc.) in either eye.

          3. Subjects who have significant anterior segment pathology that might increase
             intraoperative risk or compromise IOL stability (e.g., pseudoexfoliation syndrome,
             synechiae, iris atrophy, traumatic cataract, lens subluxation, traumatic zonulolysis,
             zonular dialysis, evident zonular weakness or dehiscence, hypermature or brunescent
             cataract, etc.) in either eye.

          4. Subjects who have uncontrolled glaucoma in either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Bausch health companies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Rodgers, PhD</last_name>
    <phone>9085418615</phone>
    <email>stephen.rodgers@bauschhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anya Loncaric</last_name>
    <phone>9085418615</phone>
    <email>aloncaric@solta.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bausch Site 108</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 113</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>02843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 115</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 103</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 107</name>
      <address>
        <city>Mount Dora</city>
        <state>Florida</state>
        <zip>32757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 101</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 102</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 106</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 109</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 112</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 110</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 104</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 105</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bausch Site 111</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

